Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers

Simon R Best, Kevin J. Niparko, Sara I. Pai

Research output: Contribution to journalArticle

Abstract

This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.

Original languageEnglish (US)
Pages (from-to)807-822
Number of pages16
JournalOtolaryngologic Clinics of North America
Volume45
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

Papillomavirus Infections
Head and Neck Neoplasms
Vaccines
Therapeutics
Virus Diseases
Primary Prevention
Mucous Membrane
Infection

Keywords

  • HPV-head and neck cancer
  • Immunotherapy
  • Oropharyngeal cancer
  • Vaccines

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers. / Best, Simon R; Niparko, Kevin J.; Pai, Sara I.

In: Otolaryngologic Clinics of North America, Vol. 45, No. 4, 08.2012, p. 807-822.

Research output: Contribution to journalArticle

@article{b2f499eaafd143668ce8a0e403891dbb,
title = "Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers",
abstract = "This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.",
keywords = "HPV-head and neck cancer, Immunotherapy, Oropharyngeal cancer, Vaccines",
author = "Best, {Simon R} and Niparko, {Kevin J.} and Pai, {Sara I.}",
year = "2012",
month = "8",
doi = "10.1016/j.otc.2012.04.005",
language = "English (US)",
volume = "45",
pages = "807--822",
journal = "Otolaryngologic Clinics of North America",
issn = "0030-6665",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers

AU - Best, Simon R

AU - Niparko, Kevin J.

AU - Pai, Sara I.

PY - 2012/8

Y1 - 2012/8

N2 - This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.

AB - This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.

KW - HPV-head and neck cancer

KW - Immunotherapy

KW - Oropharyngeal cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84863869305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863869305&partnerID=8YFLogxK

U2 - 10.1016/j.otc.2012.04.005

DO - 10.1016/j.otc.2012.04.005

M3 - Article

C2 - 22793854

AN - SCOPUS:84863869305

VL - 45

SP - 807

EP - 822

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

SN - 0030-6665

IS - 4

ER -